Locations:
Search IconSearch
August 17, 2021/Neurosciences/Podcast

Neurosarcoidosis: Complexities in Its Differential Diagnosis and Care (Podcast)

Diagnosis and treatment depend on clinical manifestations, which vary widely

The clinical manifestations and course of sarcoidosis vary, in part because the tiny collections of granulomas associated with this chronic disease can occur in any part of the body. The most common manifestations of neurosarcoidosis, which affects approximately 5% of sarcoid patients, include cranial neuropathy, polycranial neuropathy and meningitis.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Conducting a systemic evaluation to find a biopsy target is essential when trying to diagnose sarcoidosis, says Brandon Moss, MD, a neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis who also sees patients in its Sarcoidosis Center. “As they say, tissue is the issue,” he notes, “so the main job is to try and get biopsy proof of granulomatous disease.”

In the newest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Moss discusses neurosarcoidosis, the complexity of its differential diagnosis and other management issues. He delves into:

  • The prevalence of sarcoidosis and typical patient population
  • Presentation and diagnosis of the chronic disease
  • The role of biomarkers in diagnosis and treatment response
  • Treatment approaches
  • The long-term prognosis for neurosarcoid patients

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Excerpt from the podcast

Dr. Moss: In terms of a gold standard for diagnosis for neurosarcoidosis, right now I think the most established is the Neurosarcoidosis Consortium Consensus Criteria for the Diagnosis of Sarcoidosis. These are largely based on the Zajicek criteria, which have been around for a much longer period of time. But essentially, everybody needs to have a clinical presentation and diagnostic evaluation that suggests neurosarcoidosis. And the diagnostic evaluation should include studies that are pertinent for that disease manifestation, whether it’s MRI, spinal fluid studies or EMG nerve conduction studies.

Advertisement

There should also be a thorough workup for mimics for everybody, to make sure you’re not missing some of these key players, which could also be in the differential diagnosis. After that, the diagnosis is dependent upon biopsy, and there are various levels of certainty depending upon whether or not you can get a biopsy showing granulomatous disease [see image below] and where the biopsy is. So people with possible sarcoidosis do not have biopsy evidence of granulomatous disease. People with probable neurosarcoidosis have biopsy evidence of sarcoidosis in a non-neural organ system. And people with definite neurosarcoidosis have biopsy proof of granulomatous disease within the nervous system.

An image of granuloma in meninges.

Pathology image showing a granuloma in the meninges, the key identifying feature of neurosarcoidosis.

Advertisement

Related Articles

stylized illustration of a chemical compound made up of connected multicolor spheres

What’s the Outlook for BTK Inhibitors in Progressive Multiple Sclerosis?

Despite safety concerns and mixed trial results, experts see potential for this indication

Illustration of two football helmets butting into each other with an inflamed brain underneath one helmet

A Call to Find and Validate Diagnostic Biomarkers for Chronic Traumatic Encephalopathy

Experts endorse a push to improve prevention and treatment following repetitive head injury

dr. charles bernick against decorative background with podcast icon overlay
May 18, 2026/Neurosciences/Podcast

Recognizing and Managing Alzheimer’s Disease in People With Down Syndrome (Podcast)

A population with very high lifetime risk presents care challenges and pathophysiologic insights

Dr. Dylan Wint talking to a patient in a medical office

Alzheimer’s Disease Nears an Inflection Point in Diagnosis and Care

Two Cleveland Clinic neurologists review biomarker advances, targeted therapies and unresolved clinical challenges

brain illustration covered with dots and letter labels atop a ruled grid
May 12, 2026/Neurosciences/Epilepsy

Automated Framework Matches Expert Precision in Mapping Seizure Evolution

Data-driven segmentation approach shows promise for seizure characterization with utility for clinical decision making

Illustration of  a woman's head and a glow where the brain would be

New WAM Grants Support Research on Gut-Brain Interactions, Menopause and Sarcopenia

Alzheimer’s studies delve into preventing and modifying the disease’s trajectory and impact

illustration of lumbar spine with inset showing area of defect
April 23, 2026/Neurosciences/Spine Care

Two-Level Fusion Eases Complex Bertolotti Syndrome Disability

Study finds broadly similar outcomes between MIS and open surgical approaches

Woman helping older woman as she walks with a cane

New Model Performs Well Predicting Parkinson’s Sentinel Falls

System uses clinical data routinely collected at clinical visits

Ad